New drugs to fix genetic mutations that cause cancer
Novel small molecule agents to correct pathogenic VHL missense mutations
This study is working on new treatments that can fix certain genetic changes linked to a higher chance of getting cancer, specifically for families who have a history of hereditary cancer syndromes, to help prevent cancer before it starts.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11116001 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule agents that can correct specific genetic mutations associated with a high risk of cancer. The team at Fox Chase Cancer Center is using advanced techniques to identify and screen these agents, aiming to create effective treatments for individuals with hereditary cancer syndromes. By leveraging a large database of families at high risk for cancer, the research seeks to provide targeted interventions that can prevent or intercept cancer development at an early stage.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with hereditary cancer-predisposing mutations, particularly those from families with a history of cancer.
Not a fit: Patients without hereditary cancer syndromes or those not carrying the specific genetic mutations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce the risk of cancer in individuals with specific genetic mutations.
How similar studies have performed: Similar research approaches have shown promise in developing targeted therapies for genetic mutations, indicating a potential for success in this novel initiative.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Clapper, Margie L. — Research Inst of Fox Chase Can Ctr
- Study coordinator: Clapper, Margie L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.